Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2501 - 2525 of 15829 in total
Etidocaine is marketed under the name Duranest. It is an injectable local anesthetic during surgery, labor, and delivery. Etidocaine has a long duration of activity, but has the main disadvantage of increased bleeding during oral surgery.
Approved
Matched Description: … It is an injectable local anesthetic during surgery, labor, and delivery. …
Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. Desmoid tumors are typically characterized by aberrant activation in Notch signaling. Interaction between the notch receptors and their ligands activates proteolytic cleavage by gamma-secretase; therefore, the inhibition of gamma-secretase can potentially inhibit Notch signaling...
Approved
Investigational
Matched Description: … [A262556] Interaction between the notch receptors and their ligands activates proteolytic cleavage by ... of desmoid tumors, and the final approval was based on positive results obtained in the Phase 3 DeFi ... gamma-secretase; therefore, the inhibition of gamma-secretase can potentially inhibit Notch signaling and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Gamma Secretase Inhibitors and Modulators …
Hormone receptor (HR) positive, especially estrogen receptor-positive, HER2-negative breast cancer is the most common subtype of metastatic breast cancer, resulting in more than 400,000 deaths annually. Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. Therefore, significant research...
Approved
Investigational
Matched Description: … based on favorable results obtained from the CAPItello-291 trial, where the combination of capivasertib and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
Approved
Matched Iupac: … hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}butyl]-N-tert-butyl-4-[(pyridin-3-yl)methyl
Matched Description: … A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. …
Gadodiamide is a linear, non-ionic gadolinium-based contrast agent (GBCA) that is used in magnetic resonance imaging (MRI) procedures to assist in the visualization of blood vessels.[A263086,A263091] GBCAs constitute the largest group of MR agents, and they are thought to be safer than nonionic iodinated contrast agents. Approved by the FDA...
Approved
Investigational
Matched Iupac: … gadolinium(3+) 2-[bis({2-[(carboxylatomethyl)[(methylcarbamoyl)methyl]amino]ethyl})amino]acetate …
Matched Description: … [A263086,A263091] GBCAs constitute the largest group of MR agents, and they are thought to be safer than ... macrocyclic or ionic GBCA, gadodiamide can potentially lead to more gadolinium retention in the brain and
Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are...
Approved
Investigational
Matched Iupac: … methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
Matched Description: … Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase ... broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and
Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc. Research suggests that clobetasol propionate demonstrates superior pharmacologic efficacy in the treatment of...
Approved
Investigational
Withdrawn
Matched Description: … of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. ... Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations …
Nomegestrol is an ingredient in the EMA-authorised product Zoely.
Approved
Matched Categories: … nomegestrol and estrogen ... nomegestrol and estradiol ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Progestogens and Estrogens, Sequential Preparations …
Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. sumatriptan) have seen preferential use...
Approved
Investigational
Matched Description: … lability and other cardiovascular side effects - for this reason, these medications are less suitable ... seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and ... Their use is not devoid of concerns, however, and their vasoconstrictive activity can lead to blood pressure …
Clobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.
Approved
Experimental
Investigational
Matched Description: … Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids …
Matched Categories: … clobetasol and antibiotics ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Iobitridol has been used in trials studying the diagnostic of Diagnostic Imaging, Coronary Artery Disease, Type 2 Diabetes Mellitus, and Coronary Atherosclerosis.
Approved
Investigational
Matched Description: … trials studying the diagnostic of Diagnostic Imaging, Coronary Artery Disease, Type 2 Diabetes Mellitus, and
Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients. It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.
Approved
Matched Description: … Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function …
Approved
Vet approved
An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and...
Approved
Withdrawn
Matched Description: … prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy. ... [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the …
A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (TCA) or selective serotonin reuptake inhibitors (SSRIs)....
Approved
Investigational
Matched Description: … Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide ... is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (TCA ... Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than …
Matched Categories: … Benzamides and benzamide derivatives …
An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.
Approved
Investigational
Matched Description: … in combination with estrogen, for the therapy of severe acne and hirsutism in females. ... It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, …
Matched Categories: … Antiandrogens and Estrogens ... cyproterone and estrogen ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Combination Contraceptives (with Estrogen and derivatives) …
Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by...
Approved
Investigational
Matched Iupac: … 1S,2S,3R,4R)-4-carbamimidamido-3-[(1S)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic acid
Matched Description: … The development of peramivir has been supported by the US Department of Health and Human Services as ... the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and ... in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated...
Approved
Matched Iupac: … N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-{5-methyl-4H,5H,6H,7H-[1,3]thiazolo[5,4 …
Matched Description: … INR testing, and numerous drug-drug and drug-food interactions. ... atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism ... Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting …
Matched Categories: … Blood and Blood Forming Organs …
Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut...
Approved
Investigational
Matched Iupac: … (5S,8S)-8-{[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl}-8-phenyl-1,7-diazaspiro[4.5]decan-2 …
Matched Description: … Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated ... Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and ... By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system …
Matched Categories: … Antiemetics and Antinauseants ... Alimentary Tract and Metabolism …
Iloperidone is a benzisoxazole and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. It is considered to be a second-generation antipsychotic drug with multiple receptor binding profile, although it shows high affinity towards 5-HT2A and dopamine D2 receptors. Iloperidone is currently used to...
Approved
Matched Description: … Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved ... ] with multiple receptor binding profile, although it shows high affinity towards 5-HT2A and ... [A263547] Iloperidone is currently used to treat schizophrenia and manic or mixed episodes associated …
Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of...
Approved
Investigational
Matched Description: … Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). ... in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Oxyphenisatin acetate is the pro-drug of oxyphenisatin (3,3-bis(4-hydroxyphenyl)-1H-indol-2-one). The FDA withdrew its approval for the use of oxyphenisatin acetate due to safety reasons.
Approved
Investigational
Withdrawn
Pentetreotide has been used in trials studying the diagnosis of Cushing's syndrome.
Approved
Investigational
Matched Iupac: … )(carboxymethyl)amino]ethyl}(carboxymethyl)amino)ethyl](carboxymethyl)amino}acetic acid ... 16-benzyl-4-{[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl}-7-[(1R)-1-hydroxyethyl]-13-[(1H-indol-3-yl)methyl ... 6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl]carbamoyl}-2-phenylethyl]carbamoyl}methyl
Matched Categories: … Indicators and Reagents ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Sacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and children. Treatment options for these patients...
Approved
Matched Description: … People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues ... Treatment options for these patients are limited and usually consists of a lifelong sucrose-free diet ... metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Advanced Parkinson's Disease).
Approved
Investigational
Matched Iupac: … (2S)-2-amino-3-[3-hydroxy-4-(phosphonooxy)phenyl]propanoic acid
Matched Description: … Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and
Matched Categories: … Dopa and Dopa Derivatives ... foslevodopa and decarboxylase inhibitor …
Displaying drugs 2501 - 2525 of 15829 in total